LIRANAFTATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H20N2O2S
Molecular Weight	328.429
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=CC(=N1)N(C)C(=S)OC2=CC=C3CCCCC3=C2

InChI

InChIKey=VPHPQNGOVQYUMG-UHFFFAOYSA-N

InChI=1S/C18H20N2O2S/c1-20(16-8-5-9-17(19-16)21-2)18(23)22-15-11-10-13-6-3-4-7-14(13)12-15/h5,8-12H,3-4,6-7H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C18H20N2O2S
Molecular Weight	328.429
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19194054
Curator's Comment: description was created based on several sources, including http://jocpr.com/vol5-iss11-2013/JCPR-2013-5-11-219-222.pdf

Liranafate (6-methoxy-2-N-methyl-aminopyridine-thiocarboxylic acid-(5,6,7,8 tetrahydro)-β-Naphthyl ester), a new antifungal drug, is synthesis inhibitor of squalene epoxidase inhibitor and cytoderm inhibitor, which was manufactured by Tosoh Corporation and Zenyaku Kogyo Corporation. It firstly came to the market in August 2000 in Japan. By inhibiting the squalene epoxide reactions of fungal cells and detering the synthesis of ergosterol, which is a constituent of cell membrane. The antifungal activity of Liranafate is 8 times as high as that of Tolnaftate. Liranafate is especially effective against trichophyton rubrum.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Squalene epoxidase fungal 1 Target ID: Squalene epoxidase fungal Sources: http://jocpr.com/vol5-iss11-2013/JCPR-2013-5-11-219-222.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Tinea manuum 3 Sources: http://pfxbzlx.gdvdc.com/EN/abstract/abstract13.shtml	Curative	Preclinical	Unknown Approved Use Unknown
Tinea pedis 28 Sources: http://pfxbzlx.gdvdc.com/EN/abstract/abstract13.shtml	Curative	Preclinical	Unknown Approved Use Unknown
Tinea corporis 19 Sources: http://pfxbzlx.gdvdc.com/EN/abstract/abstract13.shtml	Curative	Preclinical	Unknown Approved Use Unknown
Tinea cruris 11 Sources: http://pfxbzlx.gdvdc.com/EN/abstract/abstract13.shtml	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Anti-fungal drug liranaftate suppresses fungal element-promoted production of IL-8 in normal human keratinocytes].	2008	19001760
[Fungicidal activity of liranaftate against dermatophytes].	2009	19194054

Patents

Sample Use Guides

In Vivo Use Guide

2% cream applied once a day.

Route of Administration: Topical

In Vitro Use Guide

production of IL-8 was profoundly suppressed by the addition of liranaftate to the culture in a dose-dependent manner.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:43 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:43 GMT 2025`
Record UNII	5253IGO5X3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZEFNART

Preferred Name

English

LIRANAFTATE

Official Name

English

LIRANAFTATE [MI]

Common Name

English

liranaftate [INN]

Common Name

English

LIRANAFTATE [MART.]

Common Name

English

PIRITETRATE

Common Name

English

O-(5,6,7,8,-TETRAHYDRO-2-NAPHTHYL) 6-METHOXY-N-METHYLTHIO-2-PYRIDINECARBAMATE

Common Name

English

LIRANAFTATE [JAN]

Common Name

English

Liranaftate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C514